Summary
Johnson & Johnson's 2001 Form 10-K report, filed in March 2002, presents a robust financial picture for the fiscal year ended December 30, 2001. The company operates across three major segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics, demonstrating a diversified business model that has historically provided stability and growth. This filing highlights JNJ's consistent performance and strategic focus on innovation and global reach, underpinned by strong brand recognition and ongoing research and development efforts. Investors can look to this report for insights into the company's operational strengths and its position within the healthcare industry.
Key Highlights
- 1Johnson & Johnson operates through three primary business segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics, indicating a well-diversified revenue base.
- 2The company's global presence is significant, with operations spanning various geographic regions, suggesting broad market penetration and risk diversification.
- 3The report confirms JNJ's commitment to research and development, a critical factor for sustained growth in the pharmaceutical and medical device sectors.
- 4Strong patent and trademark protection is noted, which is essential for maintaining market share and profitability for its products.
- 5The filing indicates that the company has met all reporting requirements for the preceding 12 months, signaling good corporate governance.
- 6The aggregate market value of the voting stock held by non-affiliates was substantial, approximately $181 billion as of February 26, 2002, reflecting significant investor confidence.
- 7The number of outstanding common shares was over 3 billion as of February 26, 2002.